Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Prevention

Closed

16 to 26

Pharmaceutical / Industry

2007_566
V504-001, NCT00551187

Trial Description

Summary

The purpose of this study is to see how well V504 works and how well the body tolerates V504 when given with Gardasil.

Eligibility Criteria

Inclusion Criteria:

Females between 16- to 26-years-old

Has never had Pap testing or has only had normal Pap test results

Exclusion Criteria:

History of an abnormal cervical biopsy result

History of a positive test for HPV

History of external genital/vaginal warts

Currently a user of illegal drugs or an alcohol abuser

History of severe allergic reaction that required medical attention

Are pregnant; Received a marketed HPV vaccine

Currently enrolled in a clinical trial

Currently has or has a history of certain medical conditions or is currently taking or has taken certain medications (details will be discussed at the time of consent)

Trial Contact Information

Trial Lead Organizations/Sponsors

Merck and Company, Incorporated

Medical Monitor

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00551187
Information obtained from ClinicalTrials.gov on October 03, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.